Study: Minor Cannabinoids May Be Ready for the Spotlight

This was a meta-study that focused on "minor" cannabinoids research (not THC or CBD). It was published in November 2021 in Frontiers in Pharmacology.

It presents a current overview of the latest research about the effects of these minor cannabinoids: CBN, CBC, CBG, CBD-A, CBG-A, THC-A, CBN-A, CBDV, THCV, CBGV, and D8-THC. We used this publication to update our Cannabinoids and Effects & Ingredients pages, and have added a few new benefits as a result. You can see the compiled effectiveness info on those pages.

The authors noted that many studies showed combining different cannabinoids together was more effective than using a single, isolated cannabinoid - giving more evidence for the synergistic "Entourage Effect" among cannabinoids.

"Preclinical data and early clinical studies support the continued investigation of phytocannabinoids for the treatment of pain, inflammation, neurodegeneration, cancer and other disorders".

"The ability to combine these cannabinoids with terpenes, flavonoids, polyphenols and other cannabis-based chemicals could create countless possibilities in the era of personalized healthcare."

One of the greatest areas for medical cannabis product development is with minor cannabinoids that not only have their own unique effects, but are proven to be synergistic with other cannabinoids.

The full text paper is here at the FrontiersIn.org site.